Congenica®
Oncology

Transforming cancer care

It's time to change the way we treat cancer

With the advances in Precision Oncology, over a quarter of all individuals diagnosed with advanced cancer are now eligible for a treatment based on the genomic analysis of their tumour.

To help accelerate the diagnostic journey of patients and drive the integration of Precision Oncology into routine clinical care, Congenica has developed a fully automated diagnostic oncology platform that reduces reporting times from hours to minutes, and alleviates the pressures on expert staff.



From data to report without manual intervention

Congenica's scalable end-to-end solution provides fully hands-off, evidence-based interpretation of next-generation sequencing (NGS) data coupled with automated, user-friendly reporting of actionable insights. To support rapid treatment decisions, therapy recommendations are powered by region-specific best practice guidelines with authorised therapeutic assertations from the FDA, EMA and MHRA.

Sample information

Free-text summary

Summary of actionable findings with tumour-type specific, regional therapy recommendations

Mutational Signatures

Summary of additional driver gene variants (without associated therapies)

Audit trail



Assay information

Analysis methodology

List of transcript IDs per gene

Platform performance

Our platform uses proprietary algorithms and publicly available data sets with statistical power for evidence-based, automated driver analysis and classification for high analytical performance.

HD832 Verification	Precision (%)	Sensitivity (%)	Specificity (%)	Accuracy (%)
SNVs (>15%VAF)	**100**	**100**	**99.99**	**100**
Indels (>15%VAF)	**98.9**	**96**	**99.99**	**99.99**

Get in touch to learn more

www.congenica.com/contact-us
hello@congenica.com
@congenica

Features & benefits

Fully automated, cost-effective and scalable end-to-end solution for significantly reduced turnaround times and increased operational efficiency

Therapeutic matching based on regional best-practice guidelines with authorised therapeutic assertations from the FDA, EMA and MHRA to support prompt treatment decisions

Accurate reporting of single nucleotide variants (SNVs), insertions and deletions (indels), structural variants, microsatellite instability (MSI) and tumour mutation burden (TMB) for confident detection of causal variants

Easy-to-interpret and user-friendly report focused on actionable insights to enable rapid patient treatment

Automated, evidence-based provision of actionable insights for unbiased and accurate variant interpretation

CE/IVD approved software for highest confidence in diagnostic outcome